Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
abrdn Life Sciences InvestorsHQL +0.16%51 EV-to-FCF is 14.79 as of Jul. 28, 2026, which is 10% below its 10-year median of 16.43. GuruFocus rates HQL with a GF Score™ of 51/100 and a GF Value™ of $62.01 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 937 Asset Management companies, abrdn Life Sciences Investors ranks worse than 51.33% on this metric.
The historical rank and industry rank for abrdn Life Sciences Investors's EV-to-FCF or its related term are showing as below:
HQL'
s EV-to-FCF Range Over the Past 10 Years
Min: 14.59 Med: 16.43 Max: 19.62
Current: 14.79
During the past 9 years, the highest EV-to-FCF of abrdn Life Sciences Investors was 19.62. The lowest was 14.59. And the median was 16.43.
HQL's EV-to-FCF is ranked worse than 51.33% of 937
companies
in the Asset Management industry
Industry Median: 14.54
vs HQL: 14.79
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
abrdn Life Sciences Investors (NYSE:HQL) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
abrdn Life Sciences Investors's PE Ratio (TTM) for today is calculated as:
abrdn Life Sciences Investors's share price for today is $19.37.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. abrdn Life Sciences Investors's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $6.638.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
abrdn Life Sciences Investors EV-to-FCF Related Terms
abrdn Life Sciences Investors EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, abrdn Life Sciences Investors's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
abrdn Life Sciences Investors EV-to-FCF vs Asset Management Industry
For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where abrdn Life Sciences Investors's EV-to-FCF falls into.
abrdn Life Sciences Investors's current Enterprise Value is $589.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. abrdn Life Sciences Investors's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $39.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
abrdn Life Sciences Investors (HQL) has a EV-to-FCF of 14.79 as of Jul. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on abrdn Life Sciences Investors and its competitors. This is 10% below median its historical median of 16.43. Over the past decade, abrdn Life Sciences Investors' EV-to-FCF has ranged from 14.59 to 19.62. According to the industry distribution chart, abrdn Life Sciences Investors ranks #481 out of 937 companies in the Asset Management industry, placing it in the top 51.3%.
Is abrdn Life Sciences Investors' EV-to-FCF too high?
abrdn Life Sciences Investors' current EV-to-FCF of 14.79 is 10% below median its 10-year median of 16.43. Over the past 10 years, this metric has ranged from a low of 14.59 to a high of 19.62. The Asset Management industry median EV-to-FCF is 14.54. abrdn Life Sciences Investors' value of 14.79 is 1.7% above this industry median. Based on the distribution chart, abrdn Life Sciences Investors ranks #481 out of 937 companies in the Asset Management industry, which is below the industry midpoint. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' EV-to-FCF compare to IIM and NOAH?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #481 out of 937 companies for EV-to-FCF. This places abrdn Life Sciences Investors in the lower half of its industry. The industry median EV-to-FCF is 14.54. abrdn Life Sciences Investors' value of 14.79 is 1.7% above this benchmark. Historically, abrdn Life Sciences Investors' own EV-to-FCF has ranged from 14.59 to 19.62 over the past decade. While the company's 10-year median is 16.43 vs. the industry median of 14.54, abrdn Life Sciences Investors has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for an Asset Management company?
The median EV-to-FCF among Asset Management companies is 14.54, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. abrdn Life Sciences Investors's current EV-to-FCF of 14.79 is 1.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on abrdn Life Sciences Investors and its competitors. For the Asset Management industry, the median EV-to-FCF is 14.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current EV-to-FCF is 14.79, which is 10% below median its own 10-year median of 16.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $19.37 — trading 68.8% below its estimated fair value. The current EV-to-FCF is 14.79, which is 10% below median its 10-year median of 16.43 and 1.7% above the Asset Management industry median of 14.54. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current EV-to-FCF is 14.79 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?
Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued.
The current stock price of $19.37 is trading 68.8% below its estimated GF Value™ of $62.01.
GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.
Key valuation signals for HQL:
EV-to-FCF: 14.79 (10% below median its 10-year median of 16.43)
GF Value™: $62.01 vs. price of $19.37 (68.8% below fair value)
Industry Position: 1.7% above the Asset Management median (#481 of 937)
No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
abrdn Life Sciences Investors Business Description
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score
Get the complete analysis for HQL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HQL has been successfully added to your 
